TRAW (Traws Pharma) Short-Term Debt to Capital

Corporate company logo of Traws Pharma Inc (TRAW)

Traws Pharma, Inc. (TRAW) possesses significant market influence through the development of unique small molecules to combat COVID-19 and influenza. The company's financial position relies on attracting investment, as the drug testing stage precludes consistent profits. Historical price action reflects the value of 0.00, confirming the business's independence from market volatility and its bet on the successful implementation of innovations.

Ratio of Short-Term Indebtedness to Capital: trawspharma.com (TRAW) for 04/04/2024 - 10/31/2026

Analytical breakdowns for Traws Pharma, Inc.

- stock quotes and analyst forecast:
Stock Price Traws Pharma, Inc.|TRAW - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Traws Pharma Inc|TRAW - Enterprise Value
- book capitalization information:
Net Assets per Single Share Traws Pharma|TRAW - Accounting Value of Company|Market Value to Book Value Ratio trawspharma.com|TRAW - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Traws Pharma, Inc.|TRAW - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Traws Pharma, Inc.|TRAW - Aggregate Debt Obligations|Debt to Book Value Traws Pharma Inc|TRAW - Company Long-Term Debt|Company Short-Term Debts Traws Pharma|Quick Liquidity trawspharma.com
- company profitability and valuation multiples indicators:
TRAW - Final Profit
Fundamental valuation:Traws Pharma TRAW
Brand item of trawspharma.com

To minimize the issuer's credit risks, it is critical to assess the proportion of short-term liabilities relative to equity. This short-term leverage ratio measures the company's dependence on urgent financing, allowing for a comparison of the current debt load against the fundamental stability of Traws Pharma, Inc. (TRAW), which is particularly significant given the stable demand for antiviral drugs within government medical reserves.

Competing companies

Short-Term Debt to Capital GILD|CDTX (Cidara Therapeutics Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital NVAX (Novavax, Inc.)|Short-Term Debt to Capital curevac.com CVAC|VALN - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital VIR (Vir Biotechnology Inc)|SIGA Corp (SIGA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Emergent Bio|AVIR (Atea Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital Invivyd Corp|Short-Term Debt to Equity Ratio ENTA (Enanta Pharmaceuticals, Inc.)|INO (Inovio Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|HilleVax Corp - Short-Term Debt to Equity Ratio|Kalaris Tx - Short-Term Debt to Equity|Dyadic - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient NanoViricides, Inc. NNVC|Talphera (TLPH) - Short-Term Debt to Equity|Cocrystal Pharma Inc - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio DWTX|Short-Term Debt to Capital Qualigen Corp|Short-Term Debt to Equity AlloVir, Inc. (ALVR)|Short-Term Debt to Capital Coefficient vbivaccines.com|Virios Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VXRT (Vaxart Inc.)